Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts. From the companyâs inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901. Source
No articles found.
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
We are an established, commercial-stage diagnostics company committed to reducing ...
We are an established, commercial-stage diagnos...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Join the National Investor Network and get the latest information with your interests in mind.